Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;52:1076-1083
Published online before print November 3, 2008, doi: 10.1161/HYPERTENSIONAHA.108.123042
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
52/6/1076    most recent
HYPERTENSIONAHA.108.123042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krop, M.
Right arrow Articles by Jan Danser, A.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krop, M.
Right arrow Articles by Jan Danser, A.H.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Clinical Studies

(Hypertension. 2008;52:1076.)
© 2008 American Heart Association, Inc.


Original Articles

Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin

Manne Krop; Ingrid M. Garrelds; René J.A. de Bruin; Jeanette M.G. van Gool; Naomi D.L. Fisher; Norman K. Hollenberg; A.H. Jan Danser

From the Division of Pharmacology, Vascular and Metabolic Diseases (M.K., I.M.G., R.J.A.d.B., J.M.G.v.G., A.H.J.D.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Department of Radiology and Medicine (N.D.L.F., N.K.H.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.

Correspondence to A.H. Jan Danser, Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Room EE1418b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, the Netherlands. E-mail a.danser{at}erasmusmc.nl

The vascular effects of aliskiren last longer than expected based on its half life, and this renin inhibitor has been reported to cause a greater renin rise than other renin-angiotensin system blockers. To investigate whether aliskiren accumulation in secretory granules contributes to these phenomena, renin-synthesizing mast cells were incubated with aliskiren, washed, and exposed to forskolin in medium without aliskiren (0.1 to 1000 nmol/L). (Pro)renin concentrations were measured by renin- and prorenin-specific immunoradiometric assays, and renin activity was measured by enzyme-kinetic assay. Without aliskiren, the culture medium predominantly contained prorenin, the cells exclusively stored renin, and forskolin doubled renin release. Aliskiren dose-dependently bound to (pro)renin in the medium and cell lysates and did not alter the effect of forskolin. The aliskiren concentrations required to bind prorenin were 1 to 2 orders of magnitude higher than those needed to bind renin. Blockade of cell lysate renin activity ranged from 27±15% to 79±5%, and these percentages were identical for the renin that was released by forskolin, indicating that they represented the same renin pool, ie, the renin storage granules. Comparison of renin and prorenin measurements in blood samples obtained from human volunteers treated with aliskiren, both before and after prorenin activation, revealed that ≤30% of prorenin was detected in renin-specific assays. In conclusion, aliskiren accumulates in renin granules, thus allowing long-lasting renin-angiotensin system blockade beyond the half-life of this drug. Aliskiren also binds to prorenin. This allows its detection as renin, and might explain, in part, the renin rise during renin inhibition.


Key Words: prorenin • renin • storage granule • mast cell • aliskiren




This article has been cited by other articles:


Home page
HypertensionHome page
A.H. J. Danser
Does Prorenin Exert Angiotensin-Independent Effects In Vivo?
Hypertension, December 1, 2009; 54(6): 1218 - 1220.
[Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
K. Andersen, M. H Weinberger, C. M Constance, M. A Ali, J. Jin, M. F Prescott, and D. L Keefe
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 157 - 167.
[Abstract] [PDF]


Home page
HypertensionHome page
D. J. Campbell
Aliskiren Therapy Will Have Minimal Effect on Intracellular Renin of Renin-Producing Cells
Hypertension, February 1, 2009; 53(2): e17 - e17.
[Full Text] [PDF]


Home page
HypertensionHome page
M. Krop and A.H. Jan Danser
Response to Aliskiren Therapy Will Have Minimal Effect on Intracellular Renin of Renin-Producing Cells
Hypertension, February 1, 2009; 53(2): e18 - e18.
[Full Text] [PDF]